Please login to the form below

Not currently logged in
Email:
Password:

Cephalon CEO on leave

Cephalon CEO Frank Baldino is taking a leave of absence, with his duties being temporarily transferred to chief operating officer J Kevin Buchi

Cephalon chairman and CEO Frank Baldino is taking a medical leave of absence, with his responsibilities being temporarily transferred to chief operating officer J Kevin Buchi. The biotech company hopes that Baldino will return later this year and declined to comment on his medical condition.

Baldino, who founded the company, is 56 years old. He has been Cephalon's CEO since the company was launched 20 years ago and became chairman of the board in 1999. Under Baldino's leadership, Cephalon has launched eight products in the US and has earned a place on the Fortune 1000 annual ranking of America's largest corporations.

Before founding Cephalon, Baldino was a senior research biologist in the medical products department at EI duPont de Nemours & Company, where he was responsible for developing research strategies for identifying novel neuropharmaceutical agents. He holds a PhD in pharmacology from Temple University.

Buchi was tapped to fill the newly-created role of chief operating officer earlier this year, after a 20-year tenure with the firm that included 14 years as chief financial officer.  He joined Cephalon as controller in March 1991 and held several financial positions before being appointed chief financial officer. Earlier in his career, he held a number of financial positions with EI duPont de Nemours.

26th August 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics